These results demonstrate that TDP-43 is an effective therapeutic target for ALS/FTD, indicating the possibility of the establishment of disease-modifying therapies using TDP-43-targeting ASOs that would suppress the onset or delay the progression of TDP-43 proteinopathies, including ALS/FTD. Here, TARDBP is linked to amyotrophic lateral sclerosis.